FUNDAMENTALS · Fundamentals · KR Healthcare

JW Holdings (096760) Fundamentals 2026 — P/E 3.8x, Revenue Analysis | SniperIQ

JW Holdings (096760) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩262.9B, trading at ₩3800.00 on the KSC. This SniperIQ fundamentals page covers JW Holdings's valuation (P/E 3.8x, P/B 1.0x), profitability (net margin 7.1%), revenue (₩969.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap₩262.9B
P/E (TTM)3.8x
Net Margin7.1%
Revenue (FY25)₩969.0B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is JW Holdings's market cap?

JW Holdings (096760) has a market capitalization of approximately ₩262.9B, trading at ₩3800.00 on the KSC. Market cap moves with the live share price.

What is JW Holdings's P/E ratio?

JW Holdings's trailing twelve-month P/E ratio is 3.8x, with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is JW Holdings?

JW Holdings runs a net profit margin of 7.1%, a gross margin of 50.4%, and an operating margin of 18.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does JW Holdings generate?

JW Holdings reported revenue of ₩969.0B for fiscal year 2025, with net income of ₩58.5B and earnings per share (EPS) of 840.93. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does JW Holdings pay a dividend?

JW Holdings offers a trailing dividend yield of about 5.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is JW Holdings financially healthy?

JW Holdings carries a debt-to-equity ratio of 1.35x and a current ratio of 0.73x, with a market beta of 0.57. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is JW Holdings a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For JW Holdings (096760) the key facts are: market cap ₩262.9B, P/E 3.8x, revenue ₩969.0B, 52-week range 3145-4495. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track JW Holdings's full fundamentals live

Get JW Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: BeOne Medicines (6160) fundamentals · HLB Pharmaceutical (047920) fundamentals · Sai Life Sciences (SAILIFE) fundamentals · Toho Holdings (8129) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons